Tuesday, November 5, 2024
HomeTagsRadioligand Therapy

Radioligand Therapy

Novartis Pluvicto Approved by FDA as First Targeted Radioligand Therapy

Novartis announced today that the US Food and Drug Administration (FDA) approved Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics